Risk Factors for Aneurysm Rebleeding

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Fujian Medical University.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
Qingsong Lin, Fujian Medical University
ClinicalTrials.gov Identifier:
First received: March 25, 2012
Last updated: March 28, 2012
Last verified: March 2012
The purpose of this study is to examine the risk factors for aneurysm rebleeding.

Subarachnoid Hemorrhage, Aneurysmal

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Risk Factors in Predicting Spontaneous Intracranial Aneurysm Rebleeding During Hospitalization

Resource links provided by NLM:

Further study details as provided by Fujian Medical University:

Primary Outcome Measures:
  • Aneurysm rebleeding [ Time Frame: up to 7 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 66
Study Start Date: September 2011
Estimated Study Completion Date: April 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
the case group
The case group referred to SAH patients with aneurysm rebleeding
the control group
the control group referred to SAH patients not with aneurysm rebleeding

Detailed Description:
To investigate risk factors for spontaneous aneurysm rebleeding during hospitalization and to reach conclusions if any,of clinical signs for predicting rebleeding.

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A total of 66 SAH patients were enrolled in this study

Inclusion Criteria:

  • Individual whose clinical course was clear enough to be traced back and whose conservative treatment duration was shorter than 6 weeks was included

Exclusion Criteria:

  • Rebleeding patients with certain inducing factors such as:

    • severe emotional episode,
    • severe coughing,
    • constipation,
    • excessive activities, or
    • with coagulation disorder,or
    • with other intracranial vascular malformations,such as:

      • moyamoya disease,
      • arteriovenous malformation were excluded.
  • Also patients who rebled while angiography were excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01567449

Contact: qingsong lin, master 13489991226 lqs1210305061@163.com

China, Fujian
First Affiliated Hospital,Fujian Medical University Recruiting
Fuzhou, Fujian, China, 350005
Contact: Dezhi kang, professor    13859099988    kdz99988@sina.com   
Sponsors and Collaborators
Fujian Medical University
Study Director: Dezhi kang, professor First Affiliated Hospital of Fujian Medical University
  More Information

Responsible Party: Qingsong Lin, Junior Doctor of Neurosurgery,Principal Investigator,Clinical Doctor, Fujian Medical University
ClinicalTrials.gov Identifier: NCT01567449     History of Changes
Other Study ID Numbers: 110011 
Study First Received: March 25, 2012
Last Updated: March 28, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Subarachnoid Hemorrhage
Brain Diseases
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Intracranial Hemorrhages
Nervous System Diseases
Pathologic Processes
Vascular Diseases

ClinicalTrials.gov processed this record on May 26, 2016